Latest EXEL news

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Zacks Investment Research · Wed, 23 Sep 2026 10:50:57 -0400

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Zacks Investment Research · Mon, 21 Sep 2026 10:41:11 -0400

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B

MarketBeat · Thu, 17 Sep 2026 11:05:01 -0400

Exelixis NASDAQ: EXEL President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential collaborations, while preparing for a planned launch of zanzalintinib in metastatic colorectal cancer.

Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · Tue, 15 Sep 2026 17:31:38 -0400

Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle

MarketBeat · Tue, 15 Sep 2026 07:03:31 -0400

Exelixis NASDAQ: EXEL executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year.

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Zacks Investment Research · Mon, 14 Sep 2026 10:46:04 -0400

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises

MarketBeat · Mon, 14 Sep 2026 04:02:08 -0400

Exelixis NASDAQ: EXEL executives outlined a franchise-focused growth strategy centered on expanding CABOMETYX across renal cell carcinoma and neuroendocrine tumors while advancing zanzalintinib through multiple late-stage studies.

Market information is provided for research and visualization and is not investment advice.